Figure 3.Clinical significance of the newly-established signature. (A–C) The low-risk cohort showed an improved prognosis than its counterpart in the discovery cohort, the validation cohort, and GSE30219. (D–F) The risk levels were significantly augmented in patients of higher TNM staging.
